Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Durez

Showing results (41-50 of 118) with videos related to

Pageof 12
Sort By:
The Journal of Rheumatology|September 16, 2021
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYONDDésirée van der Heijde, Cynthia E Kartman, Li Xie, et al.
Frontiers in Immunology|September 16, 2021
Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial TissueClement Triaille, Patrick Durez, Tatiana Sokolova, et al.
Rheumatology (Oxford, England)|February 16, 2021
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPAREVibeke Strand, Namita Tundia, Martin Bergman, et al.
Canadian Journal of Physiology and Pharmacology|June 18, 2010
Effects of raloxifene treatment on the phenotype of blood monocytesKarim Zouaoui Boudjeltia, Patrick Durez, Didier Oberweis, et al.
Arthritis Research & Therapy|January 22, 2016
Higher expression of TNFα-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapyAurélie De Groof, Julie Ducreux, Frances Humby, et al.
Annals of the Rheumatic Diseases|May 31, 2022
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II studyClaire Daien, Marek Krogulec, Paul Gineste, et al.
RMD Open|June 10, 2021
Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritisCéline La, Phu Quoc Lê, Alina Ferster, et al.
Arthritis Research & Therapy|August 19, 2024
Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA CohortFrancesco Natalucci, Clément Triaille, Cécile Van Mullem, et al.
Arthritis Research & Therapy|April 30, 2020
Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA CohortStéphanie Dierckx, Tatiana Sokolova, Bernard R Lauwerys, et al.
RMD Open|February 5, 2022
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE studyRoy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
Pageof 12

Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
The Journal of Rheumatology|September 16, 2021
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYONDDésirée van der Heijde, Cynthia E Kartman, Li Xie, et al.
Frontiers in Immunology|September 16, 2021
Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial TissueClement Triaille, Patrick Durez, Tatiana Sokolova, et al.
Rheumatology (Oxford, England)|February 16, 2021
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPAREVibeke Strand, Namita Tundia, Martin Bergman, et al.
Canadian Journal of Physiology and Pharmacology|June 18, 2010
Effects of raloxifene treatment on the phenotype of blood monocytesKarim Zouaoui Boudjeltia, Patrick Durez, Didier Oberweis, et al.
Arthritis Research & Therapy|January 22, 2016
Higher expression of TNFα-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapyAurélie De Groof, Julie Ducreux, Frances Humby, et al.
Annals of the Rheumatic Diseases|May 31, 2022
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II studyClaire Daien, Marek Krogulec, Paul Gineste, et al.
RMD Open|June 10, 2021
Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritisCéline La, Phu Quoc Lê, Alina Ferster, et al.
Arthritis Research & Therapy|August 19, 2024
Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA CohortFrancesco Natalucci, Clément Triaille, Cécile Van Mullem, et al.
Arthritis Research & Therapy|April 30, 2020
Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA CohortStéphanie Dierckx, Tatiana Sokolova, Bernard R Lauwerys, et al.
RMD Open|February 5, 2022
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE studyRoy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
Pageof 12